Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine with Chemoradiotherapy in Recurrent Head and Neck Cancer
NCT00003251Phase 2Unknown
- Sponsor
- University of Illinois Chicago
- Start
- Dec 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in head and neck cancer (HNC), sponsored by University of Illinois Chicago. Primary endpoint: Efficacy and role of amifostine as a cytoprotection agent. Status: unknown.
02
Drugs
amifostine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00003251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003251.